Theratechnologies Inc T.TH

I am a bit bipolar

[stockman75]

As I watched the webinar and saw all the impressive pre-clinical results and then after reading all the posts over time from the very knowledgable folks on this message board.... 

I have concluded I am quite bipolar when it comes to the cancer program. On the one hand it is all quite impressive and seems like there is a high probability there is somehting quite massive in the works. 

On the other hand I think to myself how could it be little Thera a small canadian bio-tech could be on to a major advancement in cancer treatment. How could it be Katana sold for next to nothing? How could it be that big pharma did not pick this up? How could it be that it does not get more exposure? The list goes on in the how can it be and I conclude (at that moment of bipolarness) most likely we will not see anywhere near the preclincal results. There has to be a catch..

I know many posts so far have addressed some of these questions/concepts but I still remain bipolar. One moment I think wow this is amazing and exciting. Not just from a potential financial reward perspective but the from the aspect that this is a pretty big breakthough for cancer treatment and what this could mean for people with cancer. and that it all is coming from little bio-tech in canada. Now I know that the wise folks on the science side (and even finance side) say there is much to prove and still considerable risk that it fails in the complex human body. I get that but wow if it works somewhat close to the results in pre-clinical it will be pretty amazing. But again in the back of my mind are all those questions how can this be without anyone seeming to notice except for some people on a public message board and a few institutions. Again bipolar. Am I going crazy?!  

By the way thank you to all who have extensive knowledge on the science and finances and contribute so much information. It is truly appreciated and I wish I could add just a small amount of info compared to your frequent and knowledgeable posts. So anyway thank you all even though I know some of you don't want to tolerate the neohphytes who aren't as knowledgeable or scientific minded etc. Yes I have no problem admitting my own ignorance. :-)

[jfm1330]

After SPCEO1 before, this is the seconf similar message about how a small Canadian company could be behind something potentially big? I understand why one would think that, but at the same time, don't wonder why the stock price is not moving up. The skepticism is even among shareholders!!! Also, I would add this question to yours: How could it be that FDA gave TH1902 fast track designation

[stockman75]

Very good point JFM. And apparently I have amnesia too!  

[qwerty22]

It would be interesting to know a bit further about the role the FDA has played in shaping to early part of this program. I think it would have been equally viable to get PoC from a single indication like TNBC as it would to get it from a basket trial. It struck me from a few things that were said at the KOL event that it has been the FDA that has encouraged the basket trial approach. From the

[SPCEO1]

I was struck by how the dialogue with the FDA was characterized on Monday - it seemed like they were working very closely together and that the relationship was very good. I am not sure when the FDA typcially grants a new drug a Breakthrough Therapy designation but I would not be surprised if they got that once the phase I is completed successfully. Based on the data we have seen, which is a small

[jfm1330]

I beg to differ. While the focus is all on establishing a clear proof of concept, docetaxel is far from the ultimate weapon against all types of cancers. It is pointless for them at this point to elaborate on the potential use of other cytotoxic agents, but if the proof of concept is clearly established, it will only be the beginning. I made the comparison with Lutathera just after the

[qwerty22]

I was an academic scientist and a biotech scientist, I love both but there is a difference. Biotech works best as a goal driven process, in academic science you can allow the science to take you where it goes. The goal here is to get 1902 across the finishing line and I don't expect they'll let any fanciful ideas distract them from that. My experience is there is still a huge amount of

[JayjayUSA12007]

"...If 1902 succeeeds then the whole platform increases in value. You don't need to double or triple your clinical costs by adding a 2nd or 3rd molecule in order to see massive gains...." Excellent point, Qwerty22 ! Once SORT is proven to be the "key" to enter cancer cells, mix and match other molecules against other types of cancer would become a new paradigm for cancer

[realitycheck4u]

This post has been removed in accordance with Community Policy

[Lee430]

Agreed, that is a poweful and acurate statement that any retail investor like myself would get pretty excited about.  

[scarlet1967]

Since that purchase they did bunch  of preclinical studies/tests and the results were good could be the other way around so the program came together based on many months or years of working on their science. They send 6 cancer results to the agency and got the fast track designation based on impressive data. The process could easily been ended while ago but thankfully it didn't. I

[Wino115]

Stockman brings up a very good point --and by the way, we likely all have abundant ignorance and limited knowledge on all we talk about.  All views are helpful.  The FDA point is a good one and for almost all investments there will be some doubts one needs to analyze or accept.  I would add three more data points in how we might want to think of it. First, we do now have

[stockman75]

Thanks Wino! that really helps me put things into context and makes the scenario more believable (well of course I believe it to some extent or I wouldn't be an investor).    So maybe Thera has found that 1 in 1,000 shot... base on what others have posted seems as each day passes the odds stack a bit more and more in our favor. 

[scarlet1967]

Statically overall success rate for preclinical cancer trials is about a bit over 3% from P1 to P2 over 50%, from P2 to P3 over 30% same for P3 to approval. So although very general their purchase of Katana had only over 3% chance of success. As Wino mentioned big pharmas with great balance sheets won't take those chances as they are already either commercializing their drugs and have sizeable

[qwerty22]

I think thtx fall between two stools. They aren't big-brained boffin's with new ideas that might shape drug discovery over the next 20-30 years and they aren't Pharma with bucket loads of cash to throw at those ideas. They have to pick carefully their "lottery tickets" from what other people don't want or don't see. All they have is execution on those assets. So

[Wino115]

It would be really interesting to find out who in the FDA is their sortilin wonk. There has to be one. Not sure how we can find that out but it would be very interesting to see who it is. There's definitely a cheerleader in there for it. I had always thought the only different in TH1904 was the chemo attached.  If it's just TH19P01 with doxerubicin, they maybe it works better for

[scarlet1967]

This was posted before they have a pending application to extend their NAFLD/NASH patent to other jurisdictions, if and when they get it approved they can make all sort of deals with bigger pharmas outside Europe/US. https://patentscope.wipo.int/search/docs2/iasr/WO2020205498/pdf/dimmDOZGYcWvz1jQcMgE4AvbivC8MSNxSSxmYQVlxFdMfTUv2P2VCdKEHHn_8gkaON2